Proton pump inhibitor: Difference between revisions
imported>Robert Badgett |
imported>Robert Badgett |
||
| Line 3: | Line 3: | ||
==Metabolism== | ==Metabolism== | ||
Proton pump inhibitors are metabolized by the CYP2C19 isoenzyme of [[cytochrome P-450]]. | Proton pump inhibitors are metabolized by the CYP2C19 isoenzyme of [[cytochrome P-450]]. This may be less true for [[pantoprazole]] and [[esomeprazole]].<ref name="pmid19081411">{{cite journal |author=Siller-Matula JM, Spiel AO, Lang IM, Kreiner G, Christ G, Jilma B |title=Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel |journal=Am. Heart J. |volume=157 |issue=1 |pages=148.e1–5 |year=2009 |month=January |pmid=19081411 |doi=10.1016/j.ahj.2008.09.017 |url=http://linkinghub.elsevier.com/retrieve/pii/S0002-8703(08)00822-3 |issn=}}</ref> | ||
==Adverse effects== | ==Adverse effects== | ||
Revision as of 10:13, 14 August 2009
In medicine, proton pump inhibitors (PPI) are medications that "inhibit H(+)-K(+)-exchanging atpase. They are used as anti-ulcer agents and sometimes in place of histamine H2 antagonists for gastroesophageal reflux."[1] They are also used as part of curative [therapy for Helicobacter pylori, in combination with antibiotics.
Metabolism
Proton pump inhibitors are metabolized by the CYP2C19 isoenzyme of cytochrome P-450. This may be less true for pantoprazole and esomeprazole.[2]
Adverse effects
Proton pump inhibitors may be associated with spontaneous bacterial peritonitis.[3] These drugs may also be associated with pneumonia, Clostridium difficile diarrhea, and fractures.
Proton pump inhibitors, which are metabolized by the CYP2C19 isoenzyme of cytochrome P-450, may[4] or may not[5] increase adverse cardiac events when given to patients taking clopidogrel for coronary heart disease.
References
- ↑ Anonymous (2024), Proton pump inhibitor (English). Medical Subject Headings. U.S. National Library of Medicine.
- ↑ Siller-Matula JM, Spiel AO, Lang IM, Kreiner G, Christ G, Jilma B (January 2009). "Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel". Am. Heart J. 157 (1): 148.e1–5. DOI:10.1016/j.ahj.2008.09.017. PMID 19081411. Research Blogging.
- ↑ Bajaj JS, Zadvornova Y, Heuman DM, et al. (May 2009). "Association of proton pump inhibitor therapy with spontaneous bacterial peritonitis in cirrhotic patients with ascites". Am. J. Gastroenterol. 104 (5): 1130–4. DOI:10.1038/ajg.2009.80. PMID 19337238. Research Blogging.
- ↑ Ho PM, Maddox TM, Wang L, et al. (March 2009). "Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome". JAMA 301 (9): 937–44. DOI:10.1001/jama.2009.261. PMID 19258584. Research Blogging.
- ↑ Simon T, Verstuyft C, Mary-Krause M, et al. (January 2009). "Genetic determinants of response to clopidogrel and cardiovascular events". N. Engl. J. Med. 360 (4): 363–75. DOI:10.1056/NEJMoa0808227. PMID 19106083. Research Blogging.